Parallel group double blind randomised in patients with first episode corticosteroid sensitive nephrotic syndrome comparing time to relapse and adverse effects associated with a longer tapering steroid regimen with standard regime
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
50
60mg/m2/day (0-4 weeks); 60mg/m2 alternate days (5-6 weeks); 50mg/m2 alternate days (week 7-8); 40mg/m2 alternate days (week 9-10); 30mg/m2 alternate days (week 11-12); 20mg/m2 alternate days (week 13-14); 10mg/m2 alternate days (week 15-16)
60mg/m2/day week 0-4; 40mg/m2 on alternate days week 5-8
Institute of Child Health
London, United Kingdom
RECRUITINGTime to first relapse
Time frame: 5 months
Assessment of steroid induced morbidity
Time frame: 5 months
frequent relapsing and steroid dependant disease
Time frame: 5 months
Time to relapse
Time frame: 5 months
serious adverse events
Time frame: 5 months
use of other immunosuppressive agents
Time frame: 5 months
Achenbach child behaviour checklist
Time frame: 5 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.